shutterstock_1349460611_pavel_kapysh
Pavel Kapysh / Shutterstock.com
23 December 2019AmericasSarah Morgan

Bausch Health resolves patent litigation with Glenmark

Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali (halobetasol propionate) lotion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More on this story

Americas
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More on this story

Americas
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).